Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Can The UK Remain A First Launch Market?

Uncertainty, Modifiers and Discounts Key To NICE Methods Update

Executive Summary

More pollical support from the National Health Service and health ministers is needed to ensure the UK’s future as a desirable launch market.

You may also be interested in...



Gilead’s Trodelvy To Test UK Innovative Drug Pathway

The cancer drug is also to undergo an accelerated assessment by the European Medicines Agency.

UK’s NICE Seeks Feedback On Proposed Improvements To Its Processes

Proposals extend the health technology appraisal body's focus beyond final guidance to support for early development and real world performance.

Kite Strikes CAR-T Access & Discount Deal For Tecartus In England

Health technology assessment body NICE wants Kite to collect more evidence to prove that Tecartus can cure relapsed or refractory mantle cell lymphoma. But in the meantime, it says the CAR-T therapy should be made available on the National Health Service, making UK patients among the first in the world to be offered access to the treatment.

Related Content

Topics

UsernamePublicRestriction

Register

PS144111

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel